JP2005503432A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005503432A5 JP2005503432A5 JP2003530649A JP2003530649A JP2005503432A5 JP 2005503432 A5 JP2005503432 A5 JP 2005503432A5 JP 2003530649 A JP2003530649 A JP 2003530649A JP 2003530649 A JP2003530649 A JP 2003530649A JP 2005503432 A5 JP2005503432 A5 JP 2005503432A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- disease
- formula
- compound
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 238000004519 manufacturing process Methods 0.000 claims 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- -1 monosaccharide sulfate Chemical class 0.000 claims 4
- 230000006372 lipid accumulation Effects 0.000 claims 3
- 102100022146 Arylsulfatase A Human genes 0.000 claims 2
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 claims 2
- 208000024720 Fabry Disease Diseases 0.000 claims 2
- 208000015872 Gaucher disease Diseases 0.000 claims 2
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 claims 2
- 101000901140 Homo sapiens Arylsulfatase A Proteins 0.000 claims 2
- 208000028226 Krabbe disease Diseases 0.000 claims 2
- 241000222722 Leishmania <genus> Species 0.000 claims 2
- 102000003960 Ligases Human genes 0.000 claims 2
- 108090000364 Ligases Proteins 0.000 claims 2
- 208000010557 Lipid storage disease Diseases 0.000 claims 2
- 208000014060 Niemann-Pick disease Diseases 0.000 claims 2
- 208000022292 Tay-Sachs disease Diseases 0.000 claims 2
- 230000002378 acidificating effect Effects 0.000 claims 2
- CRQQGFGUEAVUIL-UHFFFAOYSA-N chlorothalonil Chemical compound ClC1=C(Cl)C(C#N)=C(Cl)C(C#N)=C1Cl CRQQGFGUEAVUIL-UHFFFAOYSA-N 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 208000014416 lysosomal lipid storage disease Diseases 0.000 claims 2
- 201000004792 malaria Diseases 0.000 claims 2
- 230000007935 neutral effect Effects 0.000 claims 2
- 244000045947 parasite Species 0.000 claims 2
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 2
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 102000005128 Alkaline Ceramidase Human genes 0.000 claims 1
- 108010028303 Alkaline Ceramidase Proteins 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 108090000751 Ceramidases Proteins 0.000 claims 1
- 108010005125 Ceramide cholinephosphotransferase Proteins 0.000 claims 1
- 102100036093 Ectonucleotide pyrophosphatase/phosphodiesterase family member 7 Human genes 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 101000876377 Homo sapiens Ectonucleotide pyrophosphatase/phosphodiesterase family member 7 Proteins 0.000 claims 1
- 102000006243 Neutral Ceramidase Human genes 0.000 claims 1
- 102000029797 Prion Human genes 0.000 claims 1
- 108091000054 Prion Proteins 0.000 claims 1
- 102100024550 Sphingomyelin phosphodiesterase 2 Human genes 0.000 claims 1
- 102000002579 Sphingosine N-acyltransferase Human genes 0.000 claims 1
- 108020004714 Sphingosine N-acyltransferase Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000035508 accumulation Effects 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000004442 acylamino group Chemical group 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 150000002016 disaccharides Chemical class 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 150000002772 monosaccharides Chemical class 0.000 claims 1
- 108040005466 neutral sphingomyelin phosphodiesterase activity proteins Proteins 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000006501 nitrophenyl group Chemical group 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 229950004354 phosphorylcholine Drugs 0.000 claims 1
- PYJNAPOPMIJKJZ-UHFFFAOYSA-N phosphorylcholine chloride Chemical compound [Cl-].C[N+](C)(C)CCOP(O)(O)=O PYJNAPOPMIJKJZ-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 150000003408 sphingolipids Chemical class 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IL2001/000909 WO2003027058A1 (en) | 2001-09-26 | 2001-09-26 | Sphingolipids |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005503432A JP2005503432A (ja) | 2005-02-03 |
| JP2005503432A5 true JP2005503432A5 (enExample) | 2008-11-20 |
Family
ID=11043096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003530649A Pending JP2005503432A (ja) | 2001-09-26 | 2001-09-26 | スフィンゴリピド |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1430019B1 (enExample) |
| JP (1) | JP2005503432A (enExample) |
| AT (1) | ATE453614T1 (enExample) |
| CA (1) | CA2461801A1 (enExample) |
| DE (1) | DE60140964D1 (enExample) |
| ES (1) | ES2337654T3 (enExample) |
| IL (1) | IL160850A0 (enExample) |
| WO (1) | WO2003027058A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005032462A2 (en) | 2003-02-27 | 2005-04-14 | Enzo Therapeutics, Inc. | Glucocerebroside treatment of disease |
| US9717754B2 (en) | 2003-02-27 | 2017-08-01 | Enzo Therapeutics, Inc. | Glucocerebroside treatment of disease |
| JP2007533632A (ja) | 2003-09-30 | 2007-11-22 | エンゾー セラピューティクス， インコーポレイテッド | 疾患のグルコセレブロシド処理 |
| CN101214249A (zh) | 2003-11-25 | 2008-07-09 | 纽约大学西奈山医学院 | 尼曼-皮克病的基于陪伴分子的治疗 |
| WO2007136635A1 (en) * | 2006-05-16 | 2007-11-29 | Musc Foundation For Research Development | Enhancement of radiation therapy and/or chemotherapy with acid ceramidase modulators |
| IL187247A0 (en) * | 2007-11-08 | 2008-12-29 | Hadasit Med Res Service | Novel synthetic analogs of sphingolipids |
| IL187245A0 (en) * | 2007-11-08 | 2008-12-29 | Hadasit Med Res Service | Synthetic sphingolipid analogs |
| JP5757022B2 (ja) * | 2011-09-26 | 2015-07-29 | 国立大学法人名古屋大学 | 光学活性アルキルアミノスルホンアミド誘導体の製造方法及び光学活性β−アミノアルコール誘導体 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5041441A (en) * | 1988-04-04 | 1991-08-20 | The Regents Of The University Of Michigan | Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol |
| DD275670A1 (de) * | 1988-09-20 | 1990-01-31 | Akad Wissenschaften Ddr | Verfahren zur herstellung von d,l-threo-2-amino-1(p-aminophenyl)-propan-1,3-diolen |
| DE3916072A1 (de) * | 1989-05-17 | 1990-11-22 | Thera Ges Fuer Patente | Ceramidderivate und ihre verwendung als inhibitoren der sphingolipidsynthese |
| JP3800434B2 (ja) * | 1994-05-31 | 2006-07-26 | 生化学工業株式会社 | 擬似糖脂質 |
| US5763438A (en) * | 1994-06-10 | 1998-06-09 | Seikagaku Corporation | 2-acylaminopropanol compound and medical composition |
| EP0821068A3 (en) * | 1996-03-29 | 1999-06-02 | Rohm And Haas Company | Novel sphingolipids and a process thereto |
| US5830432A (en) * | 1997-03-31 | 1998-11-03 | Amur Pharmacuticals, Inc. | Phospholipid drug derivatives |
| JP2001213858A (ja) * | 1999-11-24 | 2001-08-07 | Sagami Chem Res Center | スフィンゴシン誘導体 |
| AU2001252506A1 (en) * | 2000-04-19 | 2001-10-30 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Sphingolipids |
| FR2810037B1 (fr) * | 2000-06-09 | 2004-04-23 | Aventis Pharma Sa | Utilisation de derives de 2-aminothiazoline comme inhibiteurs de no-synthase inductible |
-
2001
- 2001-09-26 ES ES01976587T patent/ES2337654T3/es not_active Expired - Lifetime
- 2001-09-26 IL IL16085001A patent/IL160850A0/xx unknown
- 2001-09-26 WO PCT/IL2001/000909 patent/WO2003027058A1/en not_active Ceased
- 2001-09-26 DE DE60140964T patent/DE60140964D1/de not_active Expired - Lifetime
- 2001-09-26 EP EP01976587A patent/EP1430019B1/en not_active Expired - Lifetime
- 2001-09-26 AT AT01976587T patent/ATE453614T1/de not_active IP Right Cessation
- 2001-09-26 CA CA002461801A patent/CA2461801A1/en not_active Abandoned
- 2001-09-26 JP JP2003530649A patent/JP2005503432A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2260043T3 (es) | Combinacion sinergica de roflumilast y salmeterol. | |
| US6589986B2 (en) | Methods of treating anxiety disorders | |
| RU2008108887A (ru) | Жидкие составы | |
| US20170151209A1 (en) | Methods for treating bipolar disorder | |
| JP2005504749A5 (enExample) | ||
| EP0287341B1 (en) | Rectally absorbable form of l-dopa | |
| JP2008521827A5 (enExample) | ||
| BR112014028643A2 (pt) | profármaco de alta penetração, seu uso e composição farmacêutica para o tratamento de condições pulmonares | |
| AR055363A1 (es) | Formulaciones farmaceuticas que comprenden un beta 2- agonista de accion prolongada para administracion por nebulizacion | |
| JP2001513483A5 (enExample) | ||
| JP2005503432A5 (enExample) | ||
| CA3037146A1 (en) | Method of reducing thyroid-associated side effects | |
| US20100222376A1 (en) | Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders | |
| JP2025509507A5 (enExample) | ||
| EP3979985A1 (en) | Compositions and methods for treating central nervous system disorders | |
| WO2014078801A1 (en) | Methods and compositions comprising guanidines for treating biofilms | |
| JP2004513099A (ja) | 喘息を治療するためのトルテロジンの使用 | |
| CN110913851B (zh) | 治疗外伤性脑损伤的组合物和方法 | |
| AR072943A1 (es) | Estereo isomero de metil-(2-hidroxi-5-(((2-(4-hidroxifenil)-1-metiletil)amino)etil)fenil)-acetamida, mezcla de sus isomeros, proceso de preparacion del mismo, una composicion farmaceutica que contiene a dicho carbamato y uso del mismo | |
| CA2438509A1 (en) | Use of cyclohexenone derivatives for the manufacture of a medicament in the treatment of dysuria | |
| TW200822927A (en) | Method of treating movement disorders using barbituric acid derivatives | |
| US20230390223A1 (en) | Administration of antipurinergic compositions for treating nervous system disorders | |
| EP2566473A1 (en) | Dosage regimen of diaryl sulfide derivatives | |
| JP2003534317A (ja) | アレルギー性疾患を処置するためのアニリンジスルフィド誘導体 | |
| JP2006516576A5 (enExample) |